Purpose: To report the results of the ASCEND Registry of cases involving endovascular aneurysm sealing (EVAS) in combination with chimney grafts (chEVAS) for the treatment of para-and juxtarenal aortic aneurysms (AAA). Methods: A retrospective, multicenter registry established in 8 vascular centers between 2013 and 2016 recorded the treatment results and follow-up of chEVAS procedures for nonruptured AAAs; data were analyzed using standardized outcome measures. In the observation period, 154 patients (mean age 72.3±7.7 years; 124 men) underwent elective treatment for de novo juxtarenal and pararenal aneurysms and formed the study group. Results: Sixty-two (40.3%) of the cohort were treated using a single parallel graft, 54 (35.1%) with double chimneys, 27 (17.5%) with triple chimneys, and 11 (7.1%) with 4 chimneys. The 30-day mortality was 2.8%, and there were 4 perioperative strokes (1 fatal). At 1 year, the freedom from all-cause mortality was 89.8% and the freedom from aneurysm-related mortality was 94.3%. There were 3 endoleaks within 90 days of the procedure, one type Ia and 2 type Ib. The freedom from type Ia endoleaks was 95.7% at 1 year. There were no types II or III endoleaks in this series; the freedom from all endoleaks was 94.2% at 1 year. Freedom from reintervention at 1 year was 89.2%. Target vessel patency rates at 1 year were 97.7%, 99.3%, 100%, and 100% for the left renal, right renal, superior mesenteric artery, and celiac axis stents, respectively. Conclusion: The ASCEND Registry supports a proof of concept for the use of polymer technology and EVAS with parallel grafts in managing patients with complex aortic disease. The future role of chEVAS will be defined by studies that assess mid-to long-term durability.
Introduction
The treatment of abdominal aortic aneurysms (AAA) that involve the renal and visceral arteries is challenging.
Traditional repair with open surgical techniques can be achieved with low mortality and morbidity in specialized centers, but national figures suggest that open repair of suprarenal aneurysms in the United Kingdom has a mortality of 14%. 1 In addition, the proportion of patients unsuitable for open repair of complex aneurysms may approach 20% to 40%, with nearly half dying of a ruptured aneurysm. 2, 3 In an attempt to increase the proportion of patients treated and reduce mortality, custom-made fenestrated endografts (fEVAR) were introduced into clinical practice, with excellent short-term results. 4 Studies have demonstrated that this technique may be performed safely, but durability remains an issue, with 30% of patients in the GLOBALSTAR Registry requiring reintervention at 3 years. 5 Although many centers continue to report excellent results with fenestrated endografts, 6 mortality of 28% has been reported with 4-vessel fEVAR. 7 Although fEVAR was a significant advance in therapy for complex AAA, challenges remain, particularly regarding the proportion of patients anatomically suitable for custom-made endografts and the time to therapy, which precludes the use of this technique in patients requiring urgent or emergency intervention. "Off-the-shelf" fenestrated endografts have not gained great traction at present due to the limited anatomical suitability and issues with durability stemming from the allowed flexibility in the position of the fenestration. 8, 9 The use of parallel grafts with conventional bifurcated endografts was initially utilized to treat patients with complex AAA disease who needed an urgent solution. 10 Initial results provided the support for this technique to be used in the elective setting, with registry data showing encouraging results. 11, 12 In many series, the chimney technique in combination with EVAR devices (chEVAR) is associated with a significant incidence of endoleak between the main endograft and the parallel graft (gutter endoleak), which may eventually limit durability. 13 The advent of endovascular aneurysm sealing (EVAS) has introduced the use of polymer filled endobags to treat AAA.
14 Combining EVAS with parallel grafts (chEVAS) may offer some advantages as the polymer-filled endobags may create a durable seal between parallel grafts, the aortic wall, and the endobags, with a potential reduction in gutter endoleak. The present study reports results from the multicenter ASCEND Registry (Aneurysm Sealing for Complex AAA: Evaluation of Nellix Durability) investigating the application of chEVAS in the elective treatment of de novo AAAs with short or no infrarenal neck.
Methods

Study Design and Patient Population
The ASCEND Registry was a multicenter retrospective registry investigating the use of parallel grafts with EVAS in the treatment of nonruptured pararenal, juxtarenal, and suprarenal AAAs and AAAs with a short infrarenal neck. The study was carried out in 1 New Zealand and 7 European centers. Patients were entered into the study after having undergone treatment of a complex abdominal aneurysm with the Nellix EndoVascular Aneurysm Sealing System (Endologix, Irvine, CA, USA) and 1 to 4 chimney grafts between 31 July 2013 and 8 March 2016. Data were collected retrospectively using standard forms available to all participating centers. Aneurysms were treated according to local protocols, and management of each patient was at the discretion of the treating physicians. Consent for the study was obtained according to local protocols.
EVAS With Parallel Grafts (chEVAS)
The application of EVAS with parallel grafts was not standardized in this registry, as the observation period encompassed the early experience of chEVAS, which was evolving at the time of patient recruitment. In general, patients in the early part of the study were treated compassionately as they were largely unsuitable for either open surgery (on the basis of comorbidity) or for custom-made grafts (on the basis of aortic morphology or time to therapy). As the study progressed, chEVAS was performed as first-line therapy in several centers, especially in patients who required urgent treatment for large or symptomatic aneurysms.
Cases were usually planned to increase the sealing zone to >1.5 cm. The chEVAS technique has been described in multiple publications. [15] [16] [17] [18] [19] [20] Briefly, access was gained to the renal and visceral vessels using an upper limb approach. The brachial artery was most often used for cases with a single chimney and the axillary artery (with or without a conduit) for 2 or more parallel stent-grafts. The type of parallel graft used reflected the length and diameter of the graft required, as well as physician preference and availability of upper limb access. A variety of covered stents were implanted, including but not limited to Atrium Advanta V12 (Atrium Maquet Getinge Group, Mijdrecht, the Netherlands), E-ventus BX (Jotec, Hechingen, Germany), Fluency Plus (Bard Peripheral Vascular, Inc., Tempe, AZ, USA), and Viabahn (W. L. Gore & Associates, Flagstaff, AZ, USA). Self-expanding stents were usually uncovered and used for the transition zone between the end of the balloon-expandable covered stents and the native branch vessel.
The renal and visceral vessels were cannulated and a stiff wire positioned. Over this wire, sheaths (usually 6-F or 7-F) were placed to deliver balloon-expandable stents. If selfexpanding stent-grafts were employed, they were often deployed sequentially. After positioning the parallel stentgrafts, the Nellix system endobags were introduced. The tops of the Nellix stents were aligned with the top of the parallel stent-grafts. Balloons were used to protect self-expanding parallel stent-grafts during the prefill step and subsequent polymer fill of the endobags to 7 atm pressure. In cases where balloon-expandable stents were used, the Nellix stents were most often deployed initially followed by withdrawal of the protective sheaths and expansion of the parallel grafts.
Completion angiography was used to assess the technical success of the reconstruction; any further adjunctive procedures were performed as required. Follow-up was according to institutional standard but typically involved clinical and radiological assessment (typically high-resolution contrast-enhanced computed tomography angiography) at defined follow-up periods. 
Patient Population
The ASCEND Registry enrolled 154 AAA patients (mean age 72.3±7.7 years; 124 men) who underwent the chEVAS procedure between 31 July 2013 and 08 March 2016. The demographics of the patient cohort and procedure details are given in Table 1 . Notably, the mean aneurysm diameter was in excess of 6 cm (61.7±12.4 mm). Average neck length and diameter were 22.5±14.6 mm and 27.5±5.6 mm, respectively.
Definitions and Statistical Analysis
Sealing zones were described as suggested by Fillinger et al. 21 All deaths within 30 days were considered to be aneurysm-related as per consensus reporting standards. Endoleaks were classified according to established definitions, as were reinterventions to the Nellix and parallel stent-grafts. Continuous data are presented as the means ± standard deviation (interquartile range) as appropriate; categorical data are given as the counts (percentage). Kaplan-Meier estimates were utilized for survival and time-to-event analyses. The threshold of statistical significance was p<0.05. All statistical analyses were performed with SAS software (version 9.4; SAS Institute Inc, Cary, NC, USA).
Results
The mean number of parallel stent-grafts implanted was 1.9 per patient (295 total); 230 (78%) were balloon-expandable models. Sixty-two (40.3%) patients were treated using a single parallel graft, 54 (35.1%) with double chimneys, 27 (17.5%) with triple chimneys, and 11 (7.1%) with 4 chimneys (Table 1 ). In terms of seal zone (recorded in 124 patients), 13 (11%) achieved a seal in zone 9 (below the renal arteries), 72 (58%) in zone 8 (below the superior mesenteric artery), 30 (24%) in zone 7 (below the celiac axis), and 9 (7%) in zone 6 (above the celiac axis). The use of chimney procedures in this patient cohort achieved a seal zone length that differed according to the number of chimneys utilized. Patients treated with a single chimney had an average seal zone length (Table 1) 
Perioperative Mortality and Morbidity
Four (2.8%) patients died within 30 days of the index procedure. One death occurred on day 6 from gastrointestinal ischemia after treatment with a single renal chimney; the cause was considered to be visceral embolization. Two significant renal complications both resulted in death; one was on day 28 following subtotal occlusion of the bilateral renal parallel grafts. The patient required dialysis and died of subsequent multiple organ failure. The other patient suffered an iatrogenic renal injury that required treatment with coil embolization; acute renal failure and dialysis ensued, culminating in death on day 3. There were 4 perioperative strokes in patients treated with a single chimney, double chimneys, and 2 with triple chimneys. Three of the strokes affected the posterior circulation and all recovered. One patient did not regain consciousness after surgery and died on postoperative day 22.
All-Cause and Aneurysm-Related Mortality
The mean duration of follow-up was 5.6±6.4 months (range 0.1-27.5, median 3). At 1 year the freedom from all-cause mortality (Figure 2A ) was 89.8% and the freedom from aneurysm-related mortality was 94.3%. All-cause mortality differed according to the extent of the operative reconstruction. Survival estimates at 1 year for patients according to seal zone (ie, 9, 8, 7, and 6) were 100%, 88%, 93%, and 76%, respectively. Similarly, survival by reconstruction type was 92%, 90%, 88%, and 76% for patients receiving 1, 2, 3, or 4 chimney stent-grafts, respectively.
There were 2 aneurysm-related deaths after 30 days. One patient with a gutter endoleak experienced a ruptured AAA; open repair and conversion was performed, but the patient died on postoperative day 132. The second death resulted from an acute occlusion of the Nellix grafts and 1 renal chimney on postoperative day 225; the patient presented moribund, and intervention was not considered appropriate.
Endoleaks
There were 3 endoleaks within 90 days of the procedure, 1 type Ia and 2 type Ib. The type Ia endoleak was treated with coil and liquid embolotherapy. One type Ib endoleak was treated with an iliac extension and the other resolved spontaneously. The freedom from type Ia endoleaks was 95.7% at 1 year ( Figure 2B ). Freedom from type Ia endoleak estimates at 1 year for patients with sealing in zones 9, 8, 7, and 6 were 100%, 97.4%, 90.2%, and 100%, respectively.
There were 4 late type Ia endoleaks, 2 were treated with coil and liquid embolotherapy, 1 had a further aortic stent implanted, and one culminated in aneurysm rupture as mentioned above. There were no types II or III endoleaks in this series. The freedom from all endoleaks was 94.2% at 1 year.
Reintervention
Aside from endoleaks, both the Nellix stents and the parallel stent-grafts were causes for reintervention. The chimney stents required 9 reinterventions in 7 patients overall, 4 in the acute period and 5 in follow-up. Other than the reintervention for renal injury mentioned above, 8 reinterventions in 6 patients were for renal stent occlusion or stenosis. All these patients required angioplasty or further renal stenting; 2 had thrombolysis for an occluded renal stent. Four patients required reintervention on the Nellix stents, 3 with adjunctive stents for graft stenosis, and 1 thrombectomy for graft occlusion. Overall, the freedom from reintervention rate at 1 year was 89.2% ( Figure 2C ). Target vessel patency was excellent in this series, with 1-year rates of 97.7%, 99.3%, 100%, and 100% for the left renal, right renal, superior mesenteric, and celiac arteries, respectively.
Discussion
The present study reports an initial series of patients with juxtarenal and pararenal AAAs treated with EVAS and parallel stent-grafts. The early results of this technique with regard to mortality, endoleaks, and branch vessel patency appear satisfactory and confirm proof of concept of this technique. The results should be taken in the context of a technique in evolution. At the time of the data analysis, the 154 patients reported in the ASCEND study were among the first to be treated with this therapeutic application, with the technical aspects of patient selection, case planning, and procedure details still being developed.
Despite the early stage of therapeutic development, the results appear promising. It is difficult to directly compare these results to outcomes for fEVAR or chEVAR, as case selection, indications, aortic morphology, and comorbidities differ between published papers. The most analogous comparisons would appear to be with chEVAR. A systematic review of chEVAR by Li et al 22 reported a 3.8% 30-day mortality vs 2.8% in our registry patients. Their late type Ia endoleak rate reached 11.8% as compared with our 5.8% overall 12-month rate. Similarly, in a different systematic review, Lindblad et al 13 observed 4% 30-day mortality and an early type Ia endoleak rate of 13%. In comparison with these systematic reviews, the ASCEND data are favorable.
However, the systematic reviews of chEVAR would have included many early series. A more contemporary set of chEVAR data may be represented by the PROTAGORAS and PERICLES studies. 11, 12 In the real-world PERICLES registry of 517 patients, 11 the authors reported a technical success rate of 97.1%. The elective perioperative mortality was 3.7%, and the rate of early type Ia endoleaks was 7.9%, of which 2.9% remained unresolved. In the PROTAGORAS study, 12 128 patients were treated with a more standardized technique. In this study, 100% technical success was obtained. The perioperative mortality was low at 0.8%. It would appear that the extent of the aneurysmal disease was slightly different in the ASCEND and PROTAGORAS studies as the proportion of patients treated with a single chimney in the ASCEND study was 40% as compared with 64% in PROTAGORAS.
In the present study, there was a very low rate of total endoleaks (5.8% at 12 months; 1 early and 4 late), which reflects the absence of types II and III endoleaks as reported previously with EVAS. 23 Because of the fundamental differences in EVAR and EVAS, there has been debate around possible "bailout" options for patients treated with EVAS who have type Ia endoleaks. In some infrarenal studies, coil scaffolding and liquid embolic agents have been used to treat type Ia endoleaks after EVAS with good short-term efficacy. 24 Similar techniques were utilized to treat 3 of the 5 type Ia endoleaks in the ASCEND Registry, with resolution of these endoleaks to latest follow-up. Of the 2 remaining endoleaks, one was treated with a further graft extension and one gutter leak was associated with an aortic rupture.
The most prevalent cause for reintervention in this study was compression of the balloon-expandable stents in the renal arteries, which required balloon dilation in 6 patients with 2 requiring renal thrombolysis. The necessity for renal reintervention appears relatively common after chimney procedures. In the PROTAGORAS Registry, 12 there were 187 parallel grafts placed, and 8 of these chimney grafts occluded (7 in the renal arteries); 6 developed a high-grade stenosis, and there were 2 visceral grafts.
One of the fundamental differences between fEVAR and parallel grafting techniques is the necessity for an upper extremity access to place the chimney grafts in both chEVAR and chEVAS. The need to cross the vertebral arteries and aortic arch has been implicated in the pathogenesis of stroke, which appears more prevalent (3%-10%) in chimney procedures than in fEVAR. [25] [26] [27] In the present series, 4 patients had perioperative strokes, 3 of which were related to the posterior cerebral circulation; all 3 recovered. One patient with multiple cerebral territories affected did not survive. The stroke rate observed in the ASCEND study appears to be at the lower end of rates reported in the literature. 19, 28 As well as the implications for neurological complications, upper limb access must be managed with respect to hemostasis. In the ASCEND Registry, the effect of the number of chimneys placed on blood loss is instructive. In patients with a single or double chimney configuration, the mean blood loss was 280 and 261 mL, respectively. When 3 chimneys were used, the blood loss rose to a mean of 475 mL. This has implications for standardization of the procedure and the management of upper limb access.
The role of chEVAR in the armamentarium of techniques for managing pararenal and juxtarenal aneurysms remains a question of debate. Some authors have suggested that the results of chEVAR and fEVAR are similar, 27 while others maintain that the outcomes of chEVAR are a cause for concern. 29 However, due to the "off-the-shelf" nature of chEVAR and chEVAS, it seems likely that the use of parallel grafts with aortic endografts will play some role in the management of patients with complex aortic disease. One concern with chEVAR is the durability of the reconstruction and particularly the formation of gutter endoleaks. The use of polymer technology for chimney-based reconstructions is theoretically attractive as the polymer should be able to form a robust and effective seal around the parallel grafts. In addition, preliminary reports suggest that polymer-based endografts do not cause the same increase in aortic neck diameter as bifurcated endografts utilizing self-expanding stents. [30] [31] [32] The role of aortic neck dilatation as a failure mode of chEVAR has not yet been determined but may be a risk in the longer term.
Limitations
The initial clinical results of the ASCEND study are promising but must be interpreted with consideration of the limitations of the study. As with all endovascular techniques, long-term durability must remain a focus, and the results of the present study are not robust beyond 12 months. In addition, the study did not include a core laboratory for independent analysis of CT images as the results were reported by the sites. Recently, endograft migration has been identified as a midterm failure mode for EVAS, 33, 34 and so detailed analysis of aortic and endograft morphology will be important to define the indications for chEVAS and the longer term results.
As with most surgical procedures, there will be a learning curve to chEVAS, and refinement and standardization of the procedure with instructions for use will likely lead to improved outcomes and durability. Planning should reflect the need for a good aortic neck; it was notable in the present study that moving from a 1-to a 2-chimney procedure considerably increased the length of available aortic neck. Standardization and rationalization of the chimney stentgrafts with appropriate engineering compatibility testing will be essential in the future to ensure a low rate of stent failure and a reduction in gutter endoleaks. More generically, management of upper limb access will need to be refined in order to minimize blood loss in cases requiring >2 chimneys.
Conclusion
The present study supports a proof of concept for the use of polymer technology and EVAS with parallel grafts in managing patients with complex aortic disease. The future role of chEVAS will be defined by studies that assess mid-to long-term durability.
